Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 3.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,812 shares of the medical research company’s stock after buying an additional 98 shares during the quarter. Silvercrest Asset Management Group LLC’s holdings in Natera were worth $445,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. LRI Investments LLC acquired a new position in Natera during the fourth quarter worth $29,000. Blue Trust Inc. raised its holdings in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the last quarter. Principal Securities Inc. raised its holdings in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after purchasing an additional 332 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider John Fesko sold 343 shares of Natera stock in a transaction on Monday, April 21st. The stock was sold at an average price of $145.55, for a total value of $49,923.65. Following the completion of the sale, the insider now owns 156,946 shares of the company’s stock, valued at $22,843,490.30. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $151.61, for a total value of $606,440.00. Following the completion of the sale, the director now directly owns 9,704 shares of the company’s stock, valued at approximately $1,471,223.44. This represents a 29.19% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 152,436 shares of company stock valued at $22,019,079 over the last quarter. Company insiders own 7.60% of the company’s stock.

Natera Stock Performance

NASDAQ NTRA opened at $154.53 on Wednesday. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The stock has a market cap of $21.10 billion, a price-to-earnings ratio of -87.80 and a beta of 1.79. The business has a fifty day moving average of $149.13 and a 200-day moving average of $157.15. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s revenue for the quarter was up 36.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.56) earnings per share. As a group, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of several research reports. Barclays lifted their price objective on Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Saturday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. The Goldman Sachs Group lifted their price objective on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Finally, Piper Sandler lifted their price objective on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $182.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.